CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale 10% owner sold 37,445 shares at an average $37.47 ($1,403,031)
- SC 13D/A Stake Beneficial Ownership Report
- 4 Open-market sale General Counsel sold 31,553 shares at an average $36.89 ($1,164,121)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SC 13D/A Stake Beneficial Ownership Report
- 4 Open-market sale 10% owner sold 85,151 shares at an average $42.53 ($3,621,601)
- 4 Open-market sale 10% owner sold 219,853 shares at an average $44.04 ($9,682,651)
- 4 Open-market sale 10% owner sold 314,792 shares at an average $42.50 ($13,379,623)
- 4 Open-market sale 10% owner sold 390,984 shares at an average $42.18 ($16,491,046)
- 8-K Event Shareholder vote results
- 4 Grant or award Director acquired 9,969 shares (grant or award)
- 4 Grant or award Director acquired 9,969 shares (grant or award)
- 4 Grant or award Director acquired 9,969 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale 10% owner sold 489,220 shares at an average $47.40 ($23,188,152)
- 8-K Event Other events
- 4 Open-market buy Director bought 146,382 shares at $47.00 ($6,879,954)
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
Page 23 of 30 · 587 filings